Authorization

Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction

Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently researched the artificial intelligence (AI)-enabled drug safety prediction technology industry and, based on its findings, recognizes Quris with the 2022 Europe Technology Innovation Leadership Award. The innovative Quris Bio-AI Clinical Prediction Platform is the first AI breakthrough to close the clinical prediction gap by effectively predicting which drug candidates will work safely in humans.
Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction
Get access to more details on the award multi-media page - https://best-practices.frost.com/quris-technologies/"Quris AI Chip-on-Chip platform, unlike other AI-pharma solutions focusing on drug discovery, better indicates which drug candidates will safely work in humans. It uses AI to predict a drug's safety, and hence its ability to succeed, particularly in Phase 1 trials, thus avoiding the high costs of failed clinical trials for pharmaceutical companies," said Supriya Lala Kundu, a Best Practices Research analyst at Frost & Sullivan.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2023    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031